AU2002256690A1 - 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity - Google Patents
4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activityInfo
- Publication number
- AU2002256690A1 AU2002256690A1 AU2002256690A AU2002256690A AU2002256690A1 AU 2002256690 A1 AU2002256690 A1 AU 2002256690A1 AU 2002256690 A AU2002256690 A AU 2002256690A AU 2002256690 A AU2002256690 A AU 2002256690A AU 2002256690 A1 AU2002256690 A1 AU 2002256690A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- chlorophenyl
- phenyl
- formula
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
4,5-Dihvdro-1 H-pyrazole derivatives having CBi-antaqonistic activity
The present invention relates to a group of novel enantiomers of 4,5-dihydro-1 H- pyrazole derivatives having S configuration at the 4-position of their 4,5- dihydropyrazole ring, to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component.
The above mentioned (4S)-4,5-dihydro-1 H-pyrazoles are potent Cannabis-1 (CB^ receptor antagonists with utility for the treatment of psychiatric and neurological disorders.
Cannabinoids are present in the Indian hemp Cannabis Sativa L. and have been used as medicinal agents for centuries (Mechoulam, R.; Feigenbaum, J.J. Prog. Med. Chem. 1987, 24, 159). However, only within the past ten years the research in the cannabinoid area has revealed pivotal information on cannabinoid receptors and their (endogenous) agonists and antagonists. The discovery and the subsequent cloning of two different subtypes of Cannabinoid receptors (CBΪ and CB2) stimulated the search for novel cannabinoid receptor antagonists (Munro, S.; Thomas, K.L.; Abu-Shaar, M. Nature 1993, 365, 61. Matsuda, L.A.; Bonner, T.I. Cannabinoid Receptors, Pertwee, R.G. Ed. 1995, 117, Academic Press, London).
In addition, pharmaceutical companies became interested in the development of cannabinoid drugs for the treatment of diseases connected with disorders of the cannabinoid system. The wide distribution of CBΪ receptors in the brain, in combination with the strictly peripheral localisation of the CB2 receptor, makes the CB! receptor a very interesting molecular target for CNS-directed drug discovery in the areas of both psychiatric and neurological disorders (Consroe, P. Neurobiology of Disease 1998, 5, 534. Pop, E. Curr. Opin. In CPNS Investigational Drugs 1999, 1, 587. Greenberg, D.A. Drug News Perspect. 1999, 12, 458). Hitherto, three types of distinct CBΪ receptor antagonists are known. Sanofi disclosed their diarylpyrazole congeners as selective CB^ receptor antagonists. A representative example is SR-141716A, which is currently undergoing Phase II clinical development for psychotic disorders (Dutta, A.K.; Sard, H.; Ryan, W.; Razdan, R.K.; Compton, D.R.; Martin, B.R. Med. Chem. Res. 1994, 5, 54. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S.R.; McCallion, D.; Pertwee, R.; Makriyannis, A. J. Med. Chem. 1999, 42, 769. Nakamura-Palacios,
E.M.; Moerschbaecher, J.M.; Barker, L.A. CNS Drug Rev. 1999, 5, 43). Aminoaikylindoles have been disclosed as CB! receptor antagonists. A representative example is lodopravadoline (AM-630), which was introduced in
1995. AM-630 is a CB! receptor antagonist, but sometimes behaves as a weak partial agonist (Hosohata, K.; Quock, R.M.; Hosohata, Y.; Burkey, T.H.; Makriyannis, A.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Life Sc. 1997, 61, PL115). More recently, researchers from Eli Lilly described aryl-aroyl substituted benzofurans as selective CB, receptor antagonists (e.g. LY-320135) (Felder, CO;
Joyce, K.E.; Briley, E.J.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. J. Pharmacol. Exp. Ther. 1998, 284, 291 ). Recently, 3-alkyl-5,5'- diphenylimidazolidinediones were described as cannabinoid receptor ligands, which were indicated to be cannabinoid antagonists (Kanyonyo, M.; Govaerts,
S.J.; Hermans, E.; Poupaert, J.H., Lambert, D.M. Biorg. Med. Chem. Lett. 1999, 9, 2233). Interestingly, many CB! receptor antagonists have been reported to behave as inverse agonists in vitro (Landsman, R.S.; Burkey, T.H.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Eur. J. Pharmacol. 1997, 334, R1 ). Recent reviews provide a nice overview of the current status in the cannabinoid research area (Mechoulam, R.; Hanus, L; Fride, E. Prog. Med. Chem. 1998, 35, 199. Lambert, D.M. Curr. Med. Chem. 1999, 6, 635. Mechoulam, R.; Fride, E.; Di Marzo, V. Eur. J. Pharmacol. 1998, 359, 1 ).
It has now surprisingly been found that the novel enantiomers of 4,5-dihydro-1 H- pyrazole derivatives having S configuration at the 4-position of their 4,5-dihydro pyrazole ring of the formula (I), prodrugs thereof, tautomers thereof and salts thereof
wherein
- R and R, are the same or different and represent 3-pyridyl or 4-pyridyl, or phenyl which may be substituted with halogen or methoxy,
- R2 and R3 are the same or different and represent hydrogen, alkyl (1-3 C) or dimethylamino - R4 represents phenyl which may be substituted with 1 , 2 or 3 substituents selected from the group halogen, trifluoromethyl, methoxy and alkyl (1-3 C)
are much more potent and selective antagonists of the cannabis CB^receptor, than the correspondence R-enantiomer.
Due to the potent CBi antagonistic activity the compounds according to the invention are suitable for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders.
The affinity of the compounds of the invention for cannabinoid CB., receptors was determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabis CBi receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.
The cannabinoid CB! antagonistic activity of compounds of the invention was determined by functional studies using CHO cells in which human cannabinoid CB! receptors are stably expressed. Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP. Concomitant activation of CB! receptors by CB! receptor agonists (e.g. CP-55,940 or (R)-WIN-55,212-2) can attenuate the forskolin-induced accumulation of cAMP in a concentration-dependent manner. This CB, receptor-mediated response can be antagonised by CBi receptor antagonists such as the compounds of the invention.
The invention relates both to the E isomer, Z isomer and E/Z mixtures of compounds having formula (I).
The compounds can be brought into forms suitable for administration by means of usual processes using auxiliary substances and/or liquid or solid carrier materials.
The compounds of the invention having formula (III) (vide infra) can be obtained according to methods known, for example: a) EP 0021506; b) DE 2529689.
A suitable synthesis for the racemic compounds according to the present invention is the following:
Synthesis route A
Step 1 of route A Reaction of a compound having formula (III)
with a compound having formula (IV)
wherein R5 represents a lower alkyl group, such as for example 2-methyl-2- thiopseudourea, or with a suitable salt form thereof in the presence of a base. This reaction gives a 4,5-dihydro-1H-pyrazole-1-carboxamidine derivative having formula (V)
wherein the symbols have the meanings as mentioned above. Compounds having formula (V) wherein R, R1 f R2and R3 have the meaning as described herein above for compound (I) are new.
Alternatively, a compound having formula (III) is reacted with a so-called guanylating agent. Examples of such guanylating agents are 1 H-pyrazole-1 - carboxamidine and its salts (for example the hydrochloride salt) and 3,5-dimethyl- 1 H-pyrazole-1-carboxamidine and its salts (for example the nitrate salt) and the like. This reaction gives a carboxamidine derivative having formula (V).
Alternatively, a compound having formula (III) is reacted with a so-called protected guanylating agent. Examples of such protected guanylating agents are N- (benzyloxycarbonyl)-l H-pyrazole-1 -carboxamidine, N-(terf-butoxycarbonyl)-1 H- pyrazole-1 -carboxamidine and N,N'-bis-(terf-butoxycarbonyl)-1 H-pyrazole-1 - carboxamidine and the like. This reaction gives after deprotection a compound having formula (V).
Step 2 of route A
The compound having formula (V) is reacted with an optionally substituted compound of the formula R4-SO2X, wherein R4 has the above mentioned meaning and X represents a halogen atom. This reaction is preferably carried out in the presence of a base, such as triethylamine in an aprotic solvent, such as acetonitrile.
Synthesis route A1
Step 1 of route A1 Reaction of a compound having formula (III)
with a thioisocyanate derivative having formula (VI) .
NCS
SO2 (VI)
R4
This reaction is preferably carried out in an inert organic solvent, such as for example acetonitrile.
This reaction gives a thiocarboxamide derivative having formula (VII). Compounds having formula (VII) wherein R, R, and R4 have the meaning as described herein above for compound (I) are new.
Step 2 of route A1
Reaction of a compound having formula (VII) with an amine in the presence of a mercury(ll) salt, such as for example HgCI2, gives a compound having formula (I)
This reaction is preferably carried out in a polar organic solvent, such as for example acetonitrile.
Synthesis route A2
Step 1 of route A2
Reaction of a compound having formula
with a carbamate ester derivative having formula (VIII).
wherein R6 represents a lower alkyl group, for example methyl.
This reaction is preferably carried out in an inert organic solvent, such as for example 1 ,4-dioxane.
This reaction gives a 4,5-dihydropyrazole-1-carboxamide derivative having formula (IX). Compounds having formula (IX) wherein R, R^ and R4 have the meaning as described herein above for compound (I) are new.
Step 2 of route A2 Reaction of a compound having formula (IX) with a halogenating agent, such as for example PCI5, gives a 4,5-dihydropyrazole-1-carboximidoyl halogenide derivative having formula (X) .
wherein R7 represents a halogen atom, such as for example chloro. This reaction is preferably carried out in an inert organic solvent, such as for example chlorobenzene.
Compounds having formula (X) wherein R, R, and R4 have the meaning as described herein above for compound (I) and wherein R7 represents a halogen atom are new.
Step 3 of route A2
Reaction of a compound having formula (X) with an amine gives a compound having formula (I).
This reaction is preferably carried out in an inert organic solvent, such as for example dichloromethane.
Synthesis route A3
Step 1 of route A3
Reaction of a compound having formula
with a dithioimidocarbonic ester derivative having formula (XI)
wherein R8 represents a C1-3 alkyl group.
This reaction is preferably carried out in a polar organic solvent, such as for example acetonitrile.
This reaction gives a carboximidothioic ester derivative having fomula (XII).
Compounds having formula (XII) wherein R, R^ and R4 have the meaning as described herein above for compound (I) and wherein R8 represents a C1-3 alkyl group are new.
Step 2 of route A3
Reaction of a compound having formula (XII) with an amine gives a compound having formula (I). This reaction is preferably carried out in a polar organic solvent, such as for example methanol.
Example I 3-(4-Chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-phenyl-1 H- pyrazole-1 -carboxamidine
Part A: A stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazole (5.13 gram, 20.0 mmol), 2-methyl-2-thiopseudourea hydroiodide (5.00 gram, 23.0 mmol) and pyridine (10 ml) is heated at 110 °C for 1 hour. After one night standing at room temperature diethyl ether is added and the precipitate is collected by filtration. This precipitate is washed three times with diethyl ether portions to afford a solid (9 gram). Melting point: -230 °C This solid is dissolved in methanol (20 ml). To the resulting solution is successively added a 2N sodium hydroxide solution (12 ml) and water (200 ml). The formed precipitate is collected by filtration, washed two times with diethyl ether and successively with diisopropyl ether. The resulting solid is dried in vacuo to yield 3-(4-chlorophenyl)-4,5-dihydro-
4-phenyl-1 H-pyrazole-1 -carboxamidine (5.1 gram, 88 % yield). Melting point: 187- 189 °C
Part B: To a stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H- pyrazole-1 -carboxamidine (0.50 gram, 1.68 mmol) and 4-fluorophenylsulfonyl
chloride (0.34 gram, 1.75 mmol) in acetonitrile (10 ml) is added N,N-dimethyl-4- aminopyhdine (0.020 gram, 0.175 mmol) and triethylamine (1 ml). The resulting solution is stirred at room temperature for 30 minutes. After addition of a 2N sodium hydroxide solution and extraction with ethylacetate (400 ml), the ethylacetate layer is concentrated in vacuo. The resulting crude residue is further purified by means of flash chromatography (petroleum ether/diethyl ether = 1/1 (v/v), followed by ethylacetate). Subsequent concentration in vacuo affords solid 3-(4-chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-phenyl-1 H-pyrazole- 1 -carboxamidine (0.55 gram, 72 % yield). Melting point: 214-215 °C
In an analogous manner the compounds having formula (I) listed below have been prepared:
4,5-Dihydro-N-((4-fluorophenyl)sulfonyl)-3-(4-methoxyphenyl)-4-(4-methoxy- phenyl)-1 H-pyrazole-1 -carboxamidine: Melting point: 155-156 °C 4,5-Dihydro-3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-N-((4-methoxy- phenyl)sulfonyl)-1 H-pyrazole-1 -carboxamidine: Melting point: 148-150 °C 3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-N-((2,4,6-trimethylphenyl)sulfonyl)-1 H- pyrazole-1 -carboxamidine: Melting point: 221-222 °C
Example II
N1,N1-Dimethyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamidine
Part A: A stirred mixture of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazole (12.0 gram, 46.8 mmol), [(4-chlorophenyl)sulfonyl]dithioimidocarbonic acid dimethyl ester (CAS: 13068-12-7) (9.20 gram, 31.1 mmol) and triethylamine (15 ml) in acetonitrile (200 ml) is heated at reflux temperature for 20 hours. An additional portion of 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazole (12.0 gram, 46.8 mmol) is added and the resulting mixture is heated at reflux temperature for another 16 hours. After concentration in vacuo, dichloromethane is added and the resulting solution is washed twice with water and dried over anhydrous Na2SO4. After filtration and evaporation in vacuo the residue is further purified by flash chromatography (diethyl ether/ petroleum ether = 1/1 (v/v)) to give 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5-dihydro-4-phenyl-1 H- pyrazole-1-carboximidothioic acid methyl ester (12.5 gram, 80% yield based on [(4-chlorophenyl)sulfonyl]dithioimidocarbonic acid dimethyl ester) as an amorphous solid.
Part B: To a stirred mixture of 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboximidothioic acid methyl ester (4.20 gram, 8.30 mmol) in methanol (75 ml) is added dimethylamine (10 ml) and dichloromethane (75 ml) and the resulting solution is stirred at room temperature for 6 hours. Evaporation in vacuo and subsequent flash chromatographic purification (diethyl ether/ petroleum ether = 1/1 (v/v), followed by diethyl ether) gives a solid which is further purified by recrystallisation from diisopropyl ether to yield N1-dimethyl-N2-((4-chloro-phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole- 1 -carboxamidine (2.63 gram, 63 % yield). Melting point: 182 °C
In an analogous manner the compounds having formula (I) listed below have been prepared:
N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-(3- pyridyl)-1 H-pyrazole-1 -carboxamidine. Melting point: 101 -105 °C
N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-(4- pyridyl)-1 H-pyrazole-1 -carboxamidine. Melting point: 112-115 °C
Example III N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine
Part A: To a solution of N-((4-chlorophenyl)sulfonyl)carbamic acid methyl ester (CAS: 34543-04-9) (2.99 gram, 12.0 mmol) and pyridine (4 ml) in 1 ,4-dioxane (20 ml) is added 3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazole (3.39 gram, 13.2 mmol) and the resulting mixture is stirred for 4 hours at 100 °C After concentration in vacuo the residue is dissolved in dichloromethane, successively washed with water, 1 N HCI and water, dried over anhydrous Na2SO4, filtered and concentrated in vacuo to a volume of 20 ml. Methyl-tert-butyl ether (60 ml) is added and the resulting solution is concentrated to a volume of 20 ml. The formed crystals are collected by filtration and recrystallised from methyl-te/τ-butyl ether to give 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5-dihydro-4-phenyl-1 H- pyrazole-1-carboxamide (4J5 gram, 76 % yield) Melting point: 211-214 °C
Part B: A mixture of 3-(4-chlorophenyl)-N-((4-chlorophenyl)sulfonyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamide (3.67 gram, 7J5 mmol) and phosphorus pentachloride (1.69 gram, 8.14 mmol) in chlorobenzene (40 ml) is heated at reflux for 1 hour. After thorough concentration in vacuo, the formed N-((4- chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazole-1-
carboximidoyl chloride is suspended in dichloromethane and reacted with cold methylamine (1.5 ml). After stirring at room temperature for 1 hour, the mixture is concentrated in vacuo. The residue is crystallised from diethyl ether to give N-methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl- 1 H-pyrazole-1 -carboxamidine (2.29 gram, 61 % yield). Melting point: 96-98 °C
(dec).
In an analogous manner the compounds having formula (I) listed below have been prepared: N-Methyl-N'-((3-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl -
1 H-pyrazole-1 -carboxamidine. Melting point: 156-160 °C
N-Propyl-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H- pyrazole-1 -carboxamidine. Melting point: 129-138 °C N-(2-Propyl)-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl- 1 H-pyrazole-1 -carboxamidine. Melting point: 110-112 °C
N-(2-Propyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-pyridyl)-4,5-dihydro-4-phenyl-1 H- pyrazole-1 -carboxamidine. Melting point: Amorphous.
N1-Ethyl-N1-methyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: 184 °C N1-Ethyl-N1-methyl-N2-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: 173-176 °C N1,N1-Dimethyl-N2-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: 195-196 °C N1,N -Dimethyl-N2-((3-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: 195-198 °C
N1,N1-Dimethyl-N2-((3-methoxyphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: 204-206 °C N-Ethyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H- pyrazole-1 -carboxamidine. Melting point: Amorphous. N-Dimethylamino-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: 155-159 °C N-Methyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: Amorphous. N1,N1-Dimethyl-N2-((2-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point:148-151 °C
N-Methyl-N'-((2,4-difluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine. Melting point: 85 °C
Example IV
(-)-(4S)-N-methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
(-)-(4S)-N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-
4-phenyl-1 H-pyrazole-1 -carboxamidine (7.16 gram, 0.0147 mol)) ([α25 D] = -150°, c = 0.01 , MeOH) (melting point: 169-170 °C) was obtained via chiral chromatographic separation of racemic N-methyl-N'-((4-chlorophenyl)sulfonyl)-3- (4-chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine (18 gram, 0.037 mol) using a Chiralpak AD, 20 μm chiral stationary phase. The mobile phase consisted of a mixture of hexane/ethanol (80/20 (v/v)) and 0.1 % ammonium hydroxide (25 % aqueous solution).
In an analogous manner the optically pure compounds listed below have been prepared from the corresponding racemates:
(-)-(4S)-N-Ethyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine: ([α25 D] = -126 °, c = 0.01 , CHCI3); Melting point: 172-175 °C Stationary phase: Chiralcel OD. Mobile phase: A mixture of heptane/2-propanol (85/15 (v/v)). (-)-(4S)-N-Dimethylamino-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine: ([α25 D] = -132 °, c = 0.01 , CHCI3);
Melting point: 218-224 °C Stationary phase: Chiralcel OD. Mobile phase: A mixture of heptane/2-propanol (85/15 (v/v)).
(-)-(4S)-N-Methyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine: ([α25 D] = -131 °, c = 0.01 , CHCI3);
Melting point: 157-160 °C Stationary phase: Chiralcel OD. Mobile phase: A mixture of heptane/2-propanol (85/15 (v/v)).
(-)-(4S)-N1,N1-Dimethyl-N2-((2-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine: ([α25 D] = -88 °, c = 0.01 , MeOH); Melting point: Amorphous. Stationary phase: Chiralpak AD. Mobile phase:
Ethanol.
(-)-(4S)-N-Methyl-N'-((2,4-difluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-
4-phenyl-1 H-pyrazole-1 -carboxamidine: ([α25 D] = -129 °, c = 0.01 , MeOH); Melting point: Amorphous. Chiralpak AD. Mobile phase: Methanol.
Claims (8)
1. The enantiomer having S configuration at the 4-position of their 4,5-dihydro pyrazole ring of a compound of formula (I)
wherein
- R and R< are the same or different and represent 3-pyridyl or 4-pyridyl, or phenyl which may be substituted with halogen or methoxy,
- R2 and R3 are the same or different and represent hydrogen, alkyl (1-3 C) or dimethylamino
- R4 represents phenyl which may be substituted with 1 , 2 or 3 substituents selected from the group halogen atoms, trifluoromethyl, methoxy and alkyl (1- 3 C) and tautomers, prodrugs and salts thereof.
2. A compound having formula (I) as claimed in claim 1 , wherein R is the group 4-chlorophenyl, R, is phenyl, R2 is hydrogen, R3 is methyl and R4 represents 4- chlorophenyl, and salts thereof.
3. A pharmaceutical composition containing at least one compound as claimed in claim 1 as an active component.
4. A method of preparing pharmaceutical compositions characterized in that a compound as claimed in claim 1 is brought in a form suitable for administration.
5. Process for the preparation of compounds having formula I, characterized in that the racemic mixture of a compound having formula I is separated into the levorotatory and the dextrorotatory enantiomers.
6. A method of treating psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischaemia, pain and other CNS-diseases involving cannabinoid neurotransmission, characterized in that a compound as claimed in claim 1 is used.
7. A method of treating gastrointestinal disorders involving cannabinoid neurotransmission, characterized in that a compound as claimed in claim 1 is used.
8. A method of treating cardiovascular disorders involving cannabinoid neurotransmission, characterized in that a compound as claimed in claim 1 is used.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01201062 | 2001-03-22 | ||
EP01201062.5 | 2001-03-22 | ||
PCT/EP2002/003079 WO2002076949A1 (en) | 2001-03-22 | 2002-03-18 | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002256690A1 true AU2002256690A1 (en) | 2003-03-27 |
AU2002256690B2 AU2002256690B2 (en) | 2006-05-18 |
Family
ID=8180044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002256690A Ceased AU2002256690B2 (en) | 2001-03-22 | 2002-03-18 | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1373216B1 (en) |
JP (1) | JP4373675B2 (en) |
KR (1) | KR100846614B1 (en) |
CN (1) | CN100366614C (en) |
AR (1) | AR033046A1 (en) |
AT (1) | ATE284872T1 (en) |
AU (1) | AU2002256690B2 (en) |
BR (1) | BR0205602A (en) |
CA (1) | CA2422708C (en) |
CZ (1) | CZ2003698A3 (en) |
DE (1) | DE60202270T2 (en) |
ES (1) | ES2229132T3 (en) |
HK (1) | HK1061852A1 (en) |
HU (1) | HUP0303148A3 (en) |
IL (1) | IL153508A (en) |
MX (1) | MXPA03003534A (en) |
NO (1) | NO324953B1 (en) |
NZ (1) | NZ524633A (en) |
PL (1) | PL363751A1 (en) |
PT (1) | PT1373216E (en) |
RU (1) | RU2281941C2 (en) |
SI (1) | SI1373216T1 (en) |
SK (1) | SK287592B6 (en) |
UA (1) | UA74066C2 (en) |
WO (1) | WO2002076949A1 (en) |
ZA (1) | ZA200307322B (en) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
EP1496838B1 (en) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituted amides |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AR045533A1 (en) * | 2003-09-02 | 2005-11-02 | Solvay Pharm Gmbh | USE OF AN ANTAGONIST CB1 RECEIVER COMPOUND, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD AND / OR PROPHYLAXIS OF DISEASES RELATED TO SUCH CB1 RECEIVER |
WO2005028438A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
RU2006117627A (en) * | 2003-10-24 | 2007-12-10 | Зольвай Фармасьютиклз Гмбх (De) | NEW APPLICATIONS IN MEDICINE OF COMPOUNDS WITH ANTAGONISTIC ACTIVITY RELATING TO CB1, AND COMBINED TREATMENT USING THESE COMPOUNDS |
TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
WO2005049615A1 (en) * | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists |
BRPI0507120A (en) | 2004-01-28 | 2007-06-19 | Hoffmann La Roche | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use |
CA2552940A1 (en) * | 2004-01-30 | 2005-08-18 | Solvay Pharmaceuticals B.V. | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
CN1938286A (en) | 2004-03-29 | 2007-03-28 | 默克公司 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
JP2008509146A (en) | 2004-08-06 | 2008-03-27 | メルク エンド カムパニー インコーポレーテッド | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
CA2577060A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
BRPI0517434A (en) * | 2004-10-25 | 2008-10-07 | Solvay Pharm Gmbh | pharmaceutical compositions comprising cannabinoid cb1 receptor antagonists and potassium channel openers for the treatment of type i diabetes mellitus, obesity and related conditions |
CN101094689B (en) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | Methods of treating obesity and obesity-related diseases and disorders |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
BRPI0517653A (en) | 2004-11-09 | 2008-10-14 | Hoffmann La Roche | compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases and use of the compounds |
WO2006060201A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives for the treatment of psychiatric disorders |
WO2006060186A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives for the treatment of dementia and related disorders |
PA8660701A1 (en) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | SMALL AGONISTS AND THEIR USES |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
CA2613678A1 (en) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
EP1757587A1 (en) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
JPWO2007018248A1 (en) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | Pyridone compounds |
EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
BRPI0614649A2 (en) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | hybrid polypeptides with selectable properties |
DE602006017712D1 (en) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | PHENYLPYRIDONDERIVAT |
CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
CA2627139A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
EP1953165B1 (en) | 2005-11-10 | 2012-02-01 | Msd K.K. | Aza-substituted spiro derivative |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
SG185849A1 (en) | 2006-02-23 | 2012-12-28 | Pfizer Ltd | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
AU2007245733A1 (en) * | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBX cannabinoid receptor modulators and Potassium channel modulators |
US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | Diaryl ketimine derivative |
WO2008059335A1 (en) | 2006-11-13 | 2008-05-22 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
CN101663262B (en) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
EP2998314B1 (en) | 2007-06-04 | 2020-01-22 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CN101318931B (en) * | 2007-06-04 | 2010-05-19 | 上海阳帆医药科技有限公司 | Diaryl substituted pyrazole derivative, preparation method and application thereof |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
GB2456183A (en) * | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | Alkylaminopyridine derivative |
CN101981025A (en) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
WO2010015972A1 (en) | 2008-08-06 | 2010-02-11 | Pfizer Limited | Diazepine and diazocane compounds as mc4 agonists |
CN102264228A (en) | 2008-10-22 | 2011-11-30 | 默沙东公司 | Novel cyclic benzimidazole derivatives useful for anti-diabetic agents |
PE20110852A1 (en) | 2008-10-30 | 2011-11-25 | Merck Sharp & Dohme | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS |
JP5557845B2 (en) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
CA2743489A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
WO2010079241A1 (en) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
AU2010317842A1 (en) | 2009-11-16 | 2012-07-12 | Mellitech | [1,5]-diazocin derivatives |
JP5540454B2 (en) | 2009-12-30 | 2014-07-02 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | Dipeptidyl peptidase inhibitor |
AR079935A1 (en) * | 2010-01-29 | 2012-02-29 | Abbott Healthcare Products Bv | SYNTHESIS OF DERIVATIVES OF PIRAZOLIN CARBOXAMIDINA REPLACED |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103476258B (en) | 2011-02-25 | 2017-04-26 | 默沙东公司 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EP2683701B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683698B1 (en) | 2011-03-08 | 2017-10-04 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120057A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
AR088352A1 (en) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE |
US8680131B2 (en) | 2012-07-25 | 2014-03-25 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP2919779B1 (en) | 2012-11-13 | 2021-01-06 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
US11155521B2 (en) | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
RU2015140066A (en) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC BICYCLIC COMPOUNDS |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
KR102272746B1 (en) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2948349C (en) | 2014-05-09 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
CN108699043A (en) * | 2016-03-04 | 2018-10-23 | 美国政府(由卫生和人类服务部的部长所代表) | Cannabined receptor mediates compound |
RU2019114228A (en) | 2016-10-14 | 2020-11-16 | Тес Фарма С.Р.Л. | Α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE INHIBITORS |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
KR20210111248A (en) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
TW202045476A (en) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-alkyl pyrrolidine orexin receptor agonists |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
EP4341246A1 (en) * | 2021-05-17 | 2024-03-27 | The United States of America, as represented by The Secretary, Department of Health and Human Services | A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives |
WO2023196556A1 (en) * | 2022-04-07 | 2023-10-12 | Corbus Pharmaceuticals, Inc. | Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL158178B (en) * | 1974-07-12 | 1978-10-16 | Philips Nv | METHOD OF PREPARING INSECTICIDE PREPARATIONS CONTAINING A PYRAZOLINE DERIVATIVE, SO PREPARED PREPARATIONS, AND METHOD OF PREPARING PYRAZOLINE DERIVATIVES WITH INSECTICIDE ACTION. |
DE3431926A1 (en) * | 1984-08-30 | 1986-03-06 | Bayer Ag, 5090 Leverkusen | AMIDINOAZOLE |
FR2692575B1 (en) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
SK287074B6 (en) * | 2000-03-23 | 2009-11-05 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazole derivatives, methods for their preparation, intermediates and their use |
AR034160A1 (en) * | 2000-09-30 | 2004-02-04 | Gruenenthal Gmbh | SULFONILGUANIDINS, MEDICINES CONTAINING THESE COMPOUNDS AND THE USE OF SULFONILGUANIDINS |
-
2002
- 2002-03-18 UA UA2003109493A patent/UA74066C2/en unknown
- 2002-03-18 CN CNB028017773A patent/CN100366614C/en not_active Expired - Fee Related
- 2002-03-18 EP EP02726190A patent/EP1373216B1/en not_active Expired - Lifetime
- 2002-03-18 KR KR1020027018040A patent/KR100846614B1/en not_active IP Right Cessation
- 2002-03-18 AR ARP020100954A patent/AR033046A1/en unknown
- 2002-03-18 MX MXPA03003534A patent/MXPA03003534A/en active IP Right Grant
- 2002-03-18 CA CA2422708A patent/CA2422708C/en not_active Expired - Fee Related
- 2002-03-18 PT PT02726190T patent/PT1373216E/en unknown
- 2002-03-18 DE DE60202270T patent/DE60202270T2/en not_active Expired - Lifetime
- 2002-03-18 HU HU0303148A patent/HUP0303148A3/en unknown
- 2002-03-18 NZ NZ524633A patent/NZ524633A/en unknown
- 2002-03-18 ES ES02726190T patent/ES2229132T3/en not_active Expired - Lifetime
- 2002-03-18 PL PL02363751A patent/PL363751A1/en not_active IP Right Cessation
- 2002-03-18 BR BR0205602-0A patent/BR0205602A/en not_active Application Discontinuation
- 2002-03-18 WO PCT/EP2002/003079 patent/WO2002076949A1/en active IP Right Grant
- 2002-03-18 IL IL153508A patent/IL153508A/en not_active IP Right Cessation
- 2002-03-18 JP JP2002576210A patent/JP4373675B2/en not_active Expired - Fee Related
- 2002-03-18 SK SK308-2003A patent/SK287592B6/en not_active IP Right Cessation
- 2002-03-18 SI SI200230065T patent/SI1373216T1/en unknown
- 2002-03-18 CZ CZ2003698A patent/CZ2003698A3/en unknown
- 2002-03-18 AT AT02726190T patent/ATE284872T1/en active
- 2002-03-18 RU RU2003105900/04A patent/RU2281941C2/en not_active IP Right Cessation
- 2002-03-18 AU AU2002256690A patent/AU2002256690B2/en not_active Ceased
-
2003
- 2003-06-23 NO NO20032892A patent/NO324953B1/en not_active IP Right Cessation
- 2003-09-18 ZA ZA200307322A patent/ZA200307322B/en unknown
-
2004
- 2004-07-06 HK HK04104848A patent/HK1061852A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1373216B1 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
AU2002256690A1 (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
US6476060B2 (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
CA2456606C (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
AU2001242501A1 (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
AU2002333852A1 (en) | Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity | |
EP1429762A1 (en) | 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity | |
AU2002333853A1 (en) | 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity | |
ZA200207303B (en) | 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. |